Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 150 mg - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - pradaxa oral pellets are indicated for the treatment of venous thromboembolic events (vte) in pediatric patients aged 3 months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. pradaxa oral pellets are indicated to reduce the risk of recurrence of vte in pediatric patients aged 3 months to less than 12 years of age who have been previously treated. pradaxa is contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see adverse reactions (6.1)] - mechanical prosthetic heart valve [see warnings and precautions (5.4)] risk summary the limited available data on pradaxa use in pregnant women are insufficient to determine drug-associated risks for adverse developmental outcomes. there are risks to the moth

Philippines - English - FDA (Food And Drug Administration)

boehringer ingelheim animal health philippines, inc.; distributor: boehringer ingelheim animal health philippines, inc. - inactivated escherichia coli fimbrial adhesins vaccine (vet.) - suspension for injection (im) - each 2 ml (dose) contains: escherichia coli k12 (f4ab, f4ac, f4ad factor antigen) escherichia coli k12 (f5 factor antigen) escherichia coli 09 (k9 factor antigen) escherichia coli 0101 (f41 factor antigen) >2.1 sau.* 21.7 sa u.* 21.4 sa u.* 21.7 sa u.* "i sau: .s. to obtain a seroagglutinating antibody titre of 1 log10 inguine pigs

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - adalimumab (unii: fys6t7f842) (adalimumab - unii:fys6t7f842) - cyltezo is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. cyltezo can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (dmards). cyltezo is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. cyltezo can be used alone or in combination with methotrexate. cyltezo is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. cyltezo can be used alone or in combination with non-biologic dmards. cyltezo is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. cyltezo is indicated for the treatment of moderately

New Zealand - English - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - disodium cobalt edta; selenium present as sodium selenate; disodium zinc edta; oxfendazole; copper disodium edta; ethylenediamine dihydroiodide - disodium cobalt edta 1.34 g/litre; selenium present as sodium selenate 0.5 g/litre; disodium zinc edta 3.67 g/litre; oxfendazole 22.65 g/litre; copper disodium edta 13.21 g/litre; ethylenediamine dihydroiodide 1.25 g/litre - endoparasiticide

New Zealand - English - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - disodium zinc edta; abamectin; ethylenediamine dihydroiodide; selenium present as selenium edta; copper disodium edta; disodium cobalt edta - disodium zinc edta 3.67 g/litre; abamectin 1 g/litre; ethylenediamine dihydroiodide 1.25 g/litre; selenium present as selenium edta 0.5 g/litre; copper disodium edta 13.21 g/litre; disodium cobalt edta 1.34 g/litre - endoparasiticide

New Zealand - English - Ministry for Primary Industries

boehringer ingelheim animal health new zealand limited - copper present as copper disodium edta; disodium cobalt edta; abamectin; selenium present as selenium edta; ethylenediamine dihydroiodide; disodium zinc edta; praziquantel - copper present as copper disodium edta 2.1 g/litre; disodium cobalt edta 1.34 g/litre; abamectin 1 g/litre; selenium present as selenium edta 0.5 g/litre; ethylenediamine dihydroiodide 1.25 g/litre; disodium zinc edta 3.67 g/litre; praziquantel 18.8 g/litre - oral nutrient/electrolyte